We conclude that drugs inhibiting ADAM10 may have the potential to impair the leukemia-niche interaction and tumor maintenance in patients with leukemia, thereby reducing tumor burden, diminishing stem cells and increasing the effectiveness of conventional chemotherapy against leukemia. This evidence concerns the gene ADAM10 and neoplasm.